AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01557751 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Whole blood for genotyping
Description: This study requires genotyping by extracting DNA from blood sample. A blood sample will be drawn once during visit 2 (day of surgery) or any other time prior to that after the signing of informed consent. Four vacutainers of which hold 8.5 mL will be drawn during this time totaling approximately 34 mL of blood which completes the genomic sampling portion of the study.
Study NCT04681586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bright light therapy
Description: using a bright light therapy device (10.000 lux) for 30min every morning for two weeks
Study NCT04681586 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: dim red light
Description: using the same device as the active group, but with an installed filter that dims light to \<300 lux for 30min every morning for two weeks
Study NCT01016340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCS
Description: MCS-5 Softgel 5 mg
Study NCT01016340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MCS
Description: MCS-5 Softgel 5 mg
Study NCT00055809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Given SC
Study NCT00055809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00055809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT05167617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: Vit D was provided as 2000 IU daily for 3 and 6 months for patients who had mild and moderate HVD, respectively.
Study NCT02629016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness
Study NCT02629016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Study NCT00462839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood loss estimation
Description: Participants were randomized in blocks, by provider type to view either the four calibrated stations or the four non-calibrated stations. The order of the volumes within each set of stations was randomized. Participants received a data card for each station on which they wrote the volume estimated. After each station, the data card was collected. Alterations to the estimations were not allowed once the answers were recorded. Subjects were then crossed over to the other group and asked to estimate the blood volumes in the non-calibrated drapes if they had first viewed the calibrated drape or the calibrated drape if they had viewed the non-calibrated drape. The order of viewing the four volumes was again randomized. The volumes were the same at the corresponding station for the calibrated and non-calibrated stations so the impact of the calibration markings on accuracy could be determined.
Study NCT00462839 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood loss estimation
Description: Participants were randomized in blocks, by provider type to view either the four calibrated stations or the four non-calibrated stations. The order of the volumes within each set of stations was randomized. Participants received a data card for each station on which they wrote the volume estimated. After each station, the data card was collected. Alterations to the estimations were not allowed once the answers were recorded. Subjects were then crossed over to the other group and asked to estimate the blood volumes in the non-calibrated drapes if they had first viewed the calibrated drape or the calibrated drape if they had viewed the non-calibrated drape. The order of viewing the four volumes was again randomized. The volumes were the same at the corresponding station for the calibrated and non-calibrated stations so the impact of the calibration markings on accuracy could be determined.
Study NCT01507233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine sulfate
Description: Patients in this group will receive IV morphine sulfate via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour.
Study NCT01507233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL (bupivacaine liposome injectable suspension)
Description: Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac, a non-steroidal anti-inflammatory drug (NSAID), may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed.
Study NCT02185963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20mg once a daily for 12 weeks
Study NCT03017352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Study NCT03017352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT02874950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: office exercise training
Description: The exercise group, did 6 months office exercise training.
Study NCT02874950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ergonomic modification
Description: The ergonomic modification group, followed 6 months modified office ergonomic modification.
Study NCT02874950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and ergonomic
Description: The mixture group, did 6 months exercise training and also followed 6 months modified office ergonomic modification.
Study NCT02874950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group did not do any exercise and did not follow any ergonomic modification.
Study NCT00050076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-135
Description: MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks
Study NCT00050076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-135
Description: MCC-135 100 mg, tablets, orally, once daily for up to 12 weeks
Study NCT00050076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-135
Description: MCC-135 200 mg, tablets, orally, once daily for up to 12 weeks
Study NCT00050076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks
Study NCT02224053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZD9291
Description: Blood sampling to measure AZD9291
Study NCT02224053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 tablet dosing
Description: AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
Study NCT02224053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole tablet dosing
Description: Omeprzole taken from Days 1 to 5 in Period 1.
Study NCT02224053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZ5140 and AZ7550
Description: Blood samples to measure levels of AZ5140 and AZ7550
Study NCT01452776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg, tablets, orally, once daily for up to 52 weeks.
Study NCT05768620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAVE
Description: The training is designed to train spatial navigation and memory and in particular egocentric and allocentric processes
Study NCT03973073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical applications and NB-UVB
Description: combination therapy of vitiligo
Study NCT03311620 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)
Description: Biopsy samples will be collected from patients scheduled to undergo EBUS TBNA using 19g and 22g needles
Study NCT01037322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cannabidiol
Description: cannabidiol given in olive oil drops, 5 mg twice daily
Study NCT01037322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo in drops
Description: olive oil containing no drug given in drops twice daily
Study NCT02469207 — intervention group
Intervention type: OTHER
Intervention: Removal of tissue post-mortem
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Tranexamic acid (TXA)
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: labetalol
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: metformin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: nifedipine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: clindamycin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT04189120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia , superficial serratus plane block and deep serratus plane block
Description: neuroaxial thoracic epidural analgesia and regional analgesia supeficial and deep serratus plane blocks
Study NCT01712568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product (Ropinirole)
Description: one Tablet at 0 hour
Study NCT01712568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Product (REQUIP )
Description: one Tablet at 0 hour
Study NCT01201694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surface-Controlled Water Soluble Curcumin
Description: Starting dose 100 mg by mouth two times a day of a 28 day cycle.
Study NCT01201694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surface-Controlled Water Soluble Curcumin MTD
Description: Dose will be maximum tolerated dose (MTD) from Arm 1.
Study NCT03434145 — intervention group
Intervention type: OTHER
Intervention: ophthalmologic exams
Description: ophthalmologic exams such as vision, intraocular pressure, axial length and optical coherence tomography
Study NCT01097694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib mesylate
Description: Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
Study NCT00708097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaF
Description: Fluoride
Study NCT00708097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaF
Description: Fluoride
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: oxycodone
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: azithromycin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: escitalopram
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: sertraline
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT01097694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00919516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell implantation
Description: Dual intramuscular and intra-arterial injections of bone marrow mononuclear cells harvested from the iliac crest. Injection sites are determined by location of stenosis and/or occlusion on angiogram obtained prior to implantation and typically occur in three medial and three lateral sites approximating the disease location.
Study NCT01863433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Study NCT06116396 — intervention group
Intervention type: GENETIC
Intervention: Genetic analysis on isolated cells
Description: Isolation of cells from blood and urine
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: ondansetron
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Ciprofloxacin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Doxycycline
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Levofloxacin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Methylphenidate
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Sumatriptan
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Citalopram
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Cyclobenzaprine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Furosemide
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Gabapentin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Hydrochlorothiazide
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Hydroxyurea
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Rosuvastatin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Topiramate
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT00708097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00708097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaMFP
Description: Fluoride
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Trazodone
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT05768620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: This is the usual care used to train visuospatial processes
Study NCT01191294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation teaching session
Description: Simulation-based, mastery learning educational intervention in visual screening for melanoma
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Valganciclovir
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Venlafaxine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Verapamil
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Remdesivir
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Anakinra
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Fluvoxamine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Bupropion
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Duloxetine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Hydrocodone
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Levetiracetam
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Paroxetine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT03511118 — intervention group
Intervention type: DRUG
Intervention: Buprenorphine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
Study NCT02809326 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 17 week Exposure Therapy Control Arm
Description: 15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
Study NCT02809326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Management Therapy
Description: TMT consists of 29 treatment sessions administered over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during Social and Emotional Regulation (SER). Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
Study NCT02809326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive 3-Week Trauma Management Therapy
Description: Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.